MILAN–(BUSINESS WIRE)–Deenova reported today its 2020 step-by-step but relentless continued geographic expansion into Austria, Belgium, France, Germany, Portugal, Spain, and Switzerland, with three new and seasoned business development staff totaling 66 years of healthcare industry experience.
Christophe Jaffuel, Deenova’s International Business Development Director, stated: “I am extremely pleased to add Carlos Duran (formerly from Becton Dickinson-Carefusion-Rowa), Thierry Geraud (previously from Becton Dickinson-Carefusion-Pyxis) and Hilmi Sunay (recently from Omnicell-Health Robotics and Arxium-IHS Riva) to an already strong Deenova sales team. These 3 extremely talented and experienced individuals joined Deenova because of its unique technology and business approach to R.O.I., and total service solutions proven in the health care industry. I was equally impressed with Deenova’s demonstrated results when I joined the company 6 months ago, witnessing first-hand how Deenova simultaneously improves patient safety, staff satisfaction, quality and efficiency of the pharmacy and medical device tracking processes, while utilising a remarkable closed-loop-system process from prescription all the way to patient administration.”
The combined 25+ years of specific Pharmacy Automation experience and 60+ years working in the healthcare industry by Carlos Duran, Thierry Geraud, and Hilmi Sunay, the new additions to Deenova’s senior sales and marketing team, strongly positions Deenova to leapfrog other competitors in the pharmacy automation sector in its primary focused European market, building on previous world-class healthcare customer experiences.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and additionally for RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25% from baseline.
Please visit www.deenova.com for additional information on its market leading solutions.